journal article·2019-12-04Open access

Development and evaluation of doxorubicin self nanoemulsifying drug delivery system with Nigella Sativa oil against human hepatocellular carcinoma

Afreen Usmani, Anuradha Mishra, Md Arshad, Asif Jafri

Abstract

Objective The development of self nano emulsifying co-delivery system of doxorubicin and Nigella sativa oil for potentiating the anticancer effects against HepG2 cell lines.Materials and methods SNEDDS were formulated by using Labrafil and N. sativa oil (3:2% w/w), Kolliphor RH40 (15% w/w), glycerol (5% w/w) as oil phase, surfactant and co-surfactant while deionized water (75% v/v) used as an aqueous phase. Optimized SNEDDS was evaluated for drug release and in vitro anticancer efficacy in liver cancer (HepG2) cell line.Results and discussion The selected formulation (F6) has a mean particle size of 79.7 nm with PDI 0.098 and the minimum viscosity of 16.42 cps with % transmittance of 1.332 with maximum drug release of 96.968% in 32 h as compared to DOX alone. Stability data showed stable emulsion in both 250C and -40C. F6 showed improved efficacy in HepG2 cells by cytotoxicity, showed significant results p<.05 with 2.5 μg/ml of (inhibitory concentration) IC50.Conclusion The overall study displayed that co-delivery of DOX and Nigella sativa oil in the form of SNEDDS may be an efficient carrier for further in vivo studies using oral delivery in human hepatocellular carcinoma in mammals.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nigella sativa pharmacological applications · Medical Research and Islamic Perspectives · Saffron Plant Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Faculty of Pharmacy, Integral University

Molecular Endocrinology Lab, Department of Zoology, University of Lucknow

Funding

Uttar Pradesh Council for Science and Technology

References (48)

Show source-provided references
1. 10.1016/S0140-6736(18)30010-210.1016/S0140-6736(18)30010-2 ↗
2. 10.1080/21691401.2017.137428210.1080/21691401.2017.1374282 ↗
3. Usmani A, Mishra A. Current updates on risk factors of hepatocellular carcinoma. Res Rev. 2017;8:23–31.
4. 10.5599/admet.1.3.710.5599/admet.1.3.7 ↗
5. 10.1021/bi00462a01610.1021/bi00462a016 ↗
6. 10.1038/srep1602010.1038/srep16020 ↗
7. 10.1016/j.ejps.2009.04.00810.1016/j.ejps.2009.04.008 ↗
8. 10.1016/j.ijpharm.2007.01.03110.1016/j.ijpharm.2007.01.031 ↗
9. 10.1371/journal.pone.008577110.1371/journal.pone.0085771 ↗
10. 10.1016/j.jphotobiol.2014.07.00510.1016/j.jphotobiol.2014.07.005 ↗
11. Ohkawa K, Hatano T, Yamada K, et al. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma. Cancer Res. 1993;53:4238–4242.
12. Jiang SP, He SN, Li YL, et al. Preparation and characteristics of lipid nanoemulsion formulations loaded with doxorubicin. Int J Nanomed. 2013;8:31–41.
13. 10.1155/2014/76542610.1155/2014/765426 ↗
14. 10.1016/j.ejpb.2008.08.01310.1016/j.ejpb.2008.08.013 ↗
15. 10.1016/j.jconrel.2011.01.02210.1016/j.jconrel.2011.01.022 ↗
16. Sharma PC Yelne MB and Dennis TJ. Database on medicinal plants used in Ayurveda; Central Council for research on ayurveda and Siddha Gvernment of India New Delhi. 2005;6:420–440.
17. Sultan MT, Butt MS, Anjum FM, et al. Nutritional profile of indigenous cultivar of black cumin seeds and antioxidant potential of its fixed and essential oil. Pak J Bot. 2009;41(3):1321–1330.
18. 10.1016/j.sajb.2017.05.01910.1016/j.sajb.2017.05.019 ↗
19. 10.1080/0163558910951414210.1080/01635589109514142 ↗
20. 10.1016/S0378-8741(98)00241-410.1016/S0378-8741(98)00241-4 ↗
21. 10.3390/ijerph200503000510.3390/ijerph2005030005 ↗
22. 10.1007/s12013-012-9493-410.1007/s12013-012-9493-4 ↗
23. Hosseini A, Shafiee-Nick R., Mousavi SH Combination of Nigella sativa with Glycyrrhiza glabra and Zingiber officinale augments their protective effects on doxorubicin-induced toxicity in h9c2 cells. Iran J Basic Med Sci. 2014;17:993.
24. 10.5897/JPAP2013.008310.5897/JPAP2013.0083 ↗
25. 10.1111/j.1742-7843.2008.00313.x10.1111/j.1742-7843.2008.00313.x ↗
26. 10.1007/s00280-010-1386-x10.1007/s00280-010-1386-x ↗
27. 10.1615/CritRevTherDrugCarrierSyst.201400850210.1615/CritRevTherDrugCarrierSyst.2014008502 ↗
28. 10.1016/j.ijpharm.2013.05.03410.1016/j.ijpharm.2013.05.034 ↗
29. 10.1016/j.ejps.2017.09.00110.1016/j.ejps.2017.09.001 ↗
30. AOAC (Association of Official Analytical Chemists). Official methods of analysis. Gaithersburg MD. AOAC (Association of Official Analytical Chemists). Official methods of analysis. Washington, USA; 2000; 26–49.
31. 10.1016/S2221-1691(12)60128-210.1016/S2221-1691(12)60128-2 ↗
32. 10.1016/j.msec.2017.03.08810.1016/j.msec.2017.03.088 ↗
33. 10.2217/nnm-2017-004010.2217/nnm-2017-0040 ↗
34. 10.1016/j.ijpharm.2009.07.01510.1016/j.ijpharm.2009.07.015 ↗
35. 10.1016/j.molliq.2013.01.00810.1016/j.molliq.2013.01.008 ↗
36. Ahmad M, Sahabjada JA, Hussain A, et al. Development of a new rutin nanoemulsion and its application on prostate carcinoma PC3 cell line. Excli J. 2017;16:810.
37. 10.1016/j.colsurfb.2013.08.02510.1016/j.colsurfb.2013.08.025 ↗
38. 10.1080/15384101.2015.110443810.1080/15384101.2015.1104438 ↗
39. Siddiqui S, Ahamad MS, Jafri A, et al. Piperine triggers apoptosis of human oral squamous carcinoma through cell cycle arrest and mitochondrial oxidative stress. Nutr Cancer. 2017;69(5):791–799.
40. Sandhu PS, Kumar R, Beg S, et al. Natural lipids enriched self-nano-emulsifying systems for effective co-delivery of tamoxifen and naringenin: systematic approach for improved breast cancer therapeutics. Nanomedicine. 2017;13:170313.
41. 10.1371/journal.pone.011000310.1371/journal.pone.0110003 ↗
42. 10.1155/2010/78017110.1155/2010/780171 ↗
43. 10.4103/2231-4040.7979910.4103/2231-4040.79799 ↗
44. 10.1208/s12249-008-9178-x10.1208/s12249-008-9178-x ↗
45. 10.3390/pharmaceutics803002010.3390/pharmaceutics8030020 ↗
46. 10.1615/CritRevTherDrugCarrierSyst.v25.i1.2010.1615/CritRevTherDrugCarrierSyst.v25.i1.20 ↗
47. 10.1007/s12272-010-0311-510.1007/s12272-010-0311-5 ↗
48. 10.1016/j.molstruc.2017.04.00810.1016/j.molstruc.2017.04.008 ↗